Accessibility Menu
 

Polydex Pharmaceuticals

(OTC) POLXF

Current PriceN/A
Market CapN/A
Since IPO (1992)-90%
5 Year+89%
1 Year+176%
1 Month-1%

Polydex Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$4.48M

Net Income (TTM)

$2.20M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

POLXF News

No articles available.

POLXF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Polydex Pharmaceuticals

Industry

Pharmaceuticals

Employees

20

CEO

George G. Usher

Headquarters

Toronto, ON M1L 2H5, CA

POLXF Financials

Key Financial Metrics (TTM)

Gross Margin

-2%

Operating Margin

-26%

Net Income Margin

-49%

Return on Equity

-53%

Return on Capital

-29%

Return on Assets

-38%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

-1.45%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Short Interest

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$91.72K

Operating Income

$1.18M

EBITDA

$745.93K

Operating Cash Flow

$589.72K

Capital Expenditure

$68.33K

Free Cash Flow

$658.05K

Cash & ST Invst.

$375.00K

Total Debt

$1.14M

Polydex Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2009YOY CHG

Revenue

$1.06M

+13.9%

Gross Profit

$177.37K

+20.6%

Gross Margin

-16.66%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

20

N/A

Net Income

$1.38M

-33.8%

EBITDA

$1.25M

-2.9%

Quarterly Fundamentals

Name
Q4 2009YOY CHG

Net Cash

$765.09K

-230.0%

Accounts Receivable

$535.90K

+231.1%

Inventory

$1.18M

+18.0%

Long Term Debt

$566.95K

-36.3%

Short Term Debt

$573.14K

+1031.9%

Return on Assets

-38.27%

N/A

Return on Invested Capital

-29.12%

N/A

Free Cash Flow

$156.85K

-127.3%

Operating Cash Flow

$140.63K

-125.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMUNImmune Therapeutics, Inc.
$0.09-7.00%
TBPMFTetra Bio-Pharma Inc.
$0.00-26.53%
FWPAYForward Pharma A/S
$300.00-25.09%
BNOEFBionomics Limited
$0.01-14.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$41.68+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.15+0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$80.49-0.10%
IBITiShares Bitcoin Trust
$38.42+0.02%

Questions About POLXF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.